Research programme: oncology therapeutics - Neovia Oncology

Drug Profile

Research programme: oncology therapeutics - Neovia Oncology

Alternative Names: Neo 2; Neo 3; Neo 4; Neo AD1; NEV 2; NEV 3; NEV 4; NEV AD1

Latest Information Update: 03 Jun 2015

Price : $50

At a glance

  • Originator Neovia Oncology
  • Class Antineoplastics; Camptothecins; Colchicum alkaloids; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 31 May 2015 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top